| Methods |
Randomised clinical trial. |
| Participants |
Country: United Kingdom.
Sample size: 20.
Post‐randomisation drop‐out(s): not stated.
Revised sample size: 20.
Females: 11 (55%).
Mean age: 47.2 years.
Piggyback: not stated.
Conventional: not stated.
Cadaveric donor: not stated.
Live donor: not stated.
Inclusion criteria:
1. Patients undergoing orthotopic liver transplantation. |
| Interventions |
The patients were randomised to the following groups.
Group 1: intervention (n = 10).
Further details: tranexamic acid 10 mg/kg bolus dose at the start of anhepatic phase followed by 3 mg/kg/hour until the patient is transferred to ITU.
Group 2: control (n = 10). |
| Outcomes |
The outcomes reported were serious adverse effects, blood loss, and transfusion requirements. |
| Notes |
Attempts were made to contact the author in September 2011. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Comment: This information was not available. |
| Allocation concealment (selection bias) |
Unclear risk |
Comment: This information was not available. |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Comment: This information was not available. |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Comment: This information was not available. |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Comment: This information was not available. |
| Selective reporting (reporting bias) |
High risk |
Comment: Important outcomes were not reported. |
| Vested interest bias |
Unclear risk |
Comment: This information was not available. |
